All rifaximin articles
-
NewsFrom gut to brain: scientists engineer bacteria to treat severe liver-related brain dysfunction
In vivo studies showed that programmable “living medicines” could reduce brain toxins and prevent neurological symptoms of hepatic encephalopathy, offering distinct advantages over a widely prescribed antibiotic.
-
NewsIBS treatment response predicted by gut microbiome in new study
Researchers investigating irritable bowel syndrome with diarrhea observed distinct characteristics of patients’ gut microbiomes that predicted whether they responded to the low FODMAP diet or rifaximin — or did not respond to treatment.
-
NewsA review of Clostridioides difficile infection and treatments
<i>Clostridioides difficile</i> is a serious nosocomial infection that could cause from mild diarrhea to fatal colitis. Here presents a general overview that describes the current and emerging treatment practices for the prevention of <i>Clostridioides difficile</i> infection and its recourrences.
-
News‘Low risk’ antibiotic has led to an almost untreatable superbug
A new study has found that an antibiotic for liver disease patients could expose them to greater risk of a dangerous superbug.
-
NewsNovel combination therapy counters antibiotic-resistant Mycobacterium infections
Researchers have discovered a novel therapy by combining two antibiotics, rifaximin and clarithromycin, to treat Mycobacterium abscessus, a non-tuberculous mycobacterium (NTM) that causes chronic lung-related infections.